Literature DB >> 11949991

New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins.

Walter Ageno1, Alexander G G Turpie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11949991      PMCID： PMC100928     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  25 in total

1.  Management of unstable angina and myocardial infarction.

Authors:  M Cohen; A G Turpie
Journal:  Lancet       Date:  2000-09-30       Impact factor: 79.321

Review 2.  Heparin.

Authors:  J Hirsh
Journal:  N Engl J Med       Date:  1991-05-30       Impact factor: 91.245

3.  Guidelines for the early management of acute coronary syndromes: focus on antithrombotic and antiplatelet therapy.

Authors:  D Fitchett
Journal:  Can J Cardiol       Date:  2000-11       Impact factor: 5.223

4.  Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.

Authors:  S G Goodman; M Cohen; F Bigonzi; E P Gurfinkel; D R Radley; V Le Iouer; G J Fromell; C Demers; A G Turpie; R M Califf; K A Fox; A Langer
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

5.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.

Authors:  J W Eikelboom; S S Anand; K Malmberg; J I Weitz; J S Ginsberg; S Yusuf
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

6.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).

Authors: 
Journal:  Eur Heart J       Date:  1999-11       Impact factor: 29.983

7.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.

Authors:  E M Antman; M Cohen; D Radley; C McCabe; J Rush; J Premmereur; E Braunwald
Journal:  Circulation       Date:  1999-10-12       Impact factor: 29.690

8.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

9.  A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.

Authors:  J F Cade; M R Buchanan; B Boneu; P Ockelford; C J Cater; A L Cerskus; J Hirsh
Journal:  Thromb Res       Date:  1984-09-15       Impact factor: 3.944

Review 10.  Pathogenesis of thrombosis in unstable angina.

Authors:  J H Chesebro; P Zoldhelyi; V Fuster
Journal:  Am J Cardiol       Date:  1991-09-03       Impact factor: 2.778
View more
  2 in total

Review 1.  Rising to the challenge: transforming the treatment of ST-segment elevation myocardial infarction.

Authors:  William A Ghali; Cameron R Donaldson; Merril L Knudtson; Steven J Lewis; Colleen J Maxwell; Jack V Tu
Journal:  CMAJ       Date:  2003-07-08       Impact factor: 8.262

Review 2.  Primary angioplasty for ST-segment elevation myocardial infarction: ready for prime time?

Authors:  Madhu K Natarajan; Salim Yusuf
Journal:  CMAJ       Date:  2003-07-08       Impact factor: 8.262
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.